<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - PHENYLEPHRINE HYDROCHLORIDE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>PHENYLEPHRINE HYDROCHLORIDE</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Mydriasis</span>,
            </h4>
            <p class="specificity"><span class="route">To the eye</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Apply 1 drop, to be administered before procedure, then apply 1 drop after 60 minutes if required, a drop of topical anaesthetic may be applied to the eye a few minutes before using phenylephrine to prevent stinging.</li>
              <li class="dose child"><strong>For children </strong><br/>
                Apply 1 drop, to be administered before procedure, a drop of proxymetacaine topical anaesthetic may be applied to the eye a few minutes before using phenylephrine to prevent stinging.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Acute hypotension</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 2&#8211;5 mg, followed by 1&#8211;10 mg, after at least 15 minutes if required. 1 mg/1 mL solution to be used.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                100&#8211;500 micrograms, repeated as necessary after at least 15 minutes.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially up to 180 micrograms/minute, reduced to 30&#8211;60 micrograms/minute, adjusted according to response.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Priapism</span>,
            </h4>
            <p class="specificity"><span class="route">By intracavernosal injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                100&#8211;200 micrograms every 5&#8211;10 minutes; maximum 1 mg per course.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <h3 class="specificity">When used by <ph outputclass="route">eye</ph></h3>
              <p>Use only if potential benefit outweighs risk.</p>
            </section>
            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">systemic</ph> use</h3>
              <p>Avoid if possible; malformations reported following use in first trimester; fetal hypoxia and bradycardia reported in late pregnancy and labour.</p>
            </section>
      </section>



      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Hypertension</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>notKnown:</strong> Arrhythmias, hypertension, palpitation, tachycardia,
              </p>
        
          <h3>Specific side effects</h3>
              <p>
                <strong>notKnown:</strong> blurred vision, conjunctivitis on prolonged administration, coronary artery spasm, extrasystoles, hyperaemia on prolonged administration, local irritation on prolonged administration, myocardial infarction (usually after use of 10% strength in patients with pre-existing cardiovascular disease), oedema on prolonged administration, photophobia, raised intraocular pressure, transient stinging, angle-closure glaucoma, anorexia, anxiety, bradycardia (also reflex bradycardia), confusion, dyspnoea, headache, hypoxia, insomnia, nausea, peripheral ischaemia, psychosis, tremor, urinary retention, vomiting, weakness,
              </p>
        
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">systemic</ph> use in children</h3>
              <p>For <i>intravenous injection</i>, dilute to a concentration of 1&#8239;mg/mL with Water for Injections and administer slowly.</p><p>For <i>intravenous infusion</i>, dilute to a concentration of 20&#8239;micrograms/mL with Glucose 5% or Sodium Chloride 0.9% and administer as a continuous infusion via a central venous catheter using a controlled infusion device.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">systemic</ph> use in adults</h3>
              <p>For <i>intravenous infusion</i> give intermittently in Glucose 5% or Sodium chloride 0.9%. Dilute 10&#8239;mg in 500&#8239;mL infusion fluid.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intracavernosal</ph> use in adults</h3>
              <p>For <i>intracavernosal injection</i>, if suitable strength of phenylephrine injection is not available, it may be specially prepared by diluting 0.1&#8239;mL of the phenylephrine 1% (10&#8239;mg/mL) injection to 5&#8239;mL with sodium chloride 0.9%.</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

      </section>



      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
              <strong>When used by eye:</strong>
            asthma
          </li>
          <li>
              <strong>When used by eye:</strong>
            cerebral arteriosclerosis in adults
          </li>
          <li>
              <strong>When used by eye:</strong>
            corneal epithelial damage
          </li>
          <li>
              <strong>When used by eye:</strong>
            darkly pigmented iris is more resistant to pupillary dilatation and caution should be exercised to avoid overdosage.
          </li>
          <li>
              <strong>When used by eye:</strong>
            diabetes (avoid eye drops in long standing diabetes)
          </li>
          <li>
              <strong>When used by eye:</strong>
            mydriasis can precipitate acute angle-closure glaucoma in a few patients, usually over 60 years and hypermetropic (long-sighted), who are pre-disposed to the condition because of a shallow anterior chamber in adults
          </li>
          <li>
              <strong>When used by eye:</strong>
            mydriasis can precipitate acute angle-closure glaucoma in the very few children who are predisposed to the condition because of a shallow anterior chamber in children
          </li>
          <li>
              <strong>When used by eye:</strong>
            neonates are at an increased risk of systemic toxicity in neonates
          </li>
          <li>
              <strong>When used by eye:</strong>
            ocular hyperaemia
          </li>
          <li>
              <strong>When used by eye:</strong>
            susceptibility to angle-closure glaucoma
          </li>
          <li>
              <strong>With systemic use:</strong>
            coronary disease
          </li>
          <li>
              <strong>With systemic use:</strong>
            coronary vascular thrombosis
          </li>
          <li>
              <strong>With systemic use:</strong>
            diabetes (avoid eye drops in long standing diabetes)
          </li>
          <li>
              <strong>With systemic use:</strong>
            elderly in adults
          </li>
          <li>
              <strong>With systemic use:</strong>
            extravasation at injection site may cause necrosis
          </li>
          <li>
              <strong>With systemic use:</strong>
            following myocardial infarction
          </li>
          <li>
              <strong>With systemic use:</strong>
            hypercapnia
          </li>
          <li>
              <strong>With systemic use:</strong>
            hyperthyroidism
          </li>
          <li>
              <strong>With systemic use:</strong>
            hypoxia
          </li>
          <li>
              <strong>With systemic use:</strong>
            mesenteric vascular thrombosis
          </li>
          <li>
              <strong>With systemic use:</strong>
            peripheral vascular thrombosis
          </li>
          <li>
              <strong>With systemic use:</strong>
            Prinzmetal&#8217;s variant angina
          </li>
          <li>
              <strong>With systemic use:</strong>
            susceptibility to angle-closure glaucoma
          </li>
          <li>
              <strong>With systemic use:</strong>
            uncorrected hypovolaemia
          </li>
        </ul>
        <ul>
          <li>
            <p>Phenylephrine has a longer duration of action than noradrenaline (norepinephrine), and an excessive vasopressor response may cause a prolonged rise in blood pressure.</p>
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <h3 class="specificity">With <ph outputclass="route">systemic</ph> use</h3>
              <p>Contra-indicated in hypertension&#8212;monitor blood pressure and rate of flow frequently.</p>
            </section>
      </section>

      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <h3 class="specificity">With <ph outputclass="route">systemic</ph> use in children</h3>
              <p>Not licensed for use in children by intravenous infusion or injection.</p>
            </section>
            <section class="unlicensedUse">
              <h3 class="specificity">With <ph outputclass="route">systemic</ph> use in adults</h3>
              <p>Use of phenylephrine hydrochloride injection in priapism is an unlicensed indication.</p>
            </section>
      </section>

      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
              <h3 class="specificity">In children</h3>
              <p>Intravenous administration preferred when managing acute hypotension in children.</p>
            </section>
            <section class="prescribingAndDispensingInformation">
              <h3 class="specificity">When used by <ph outputclass="route">eye</ph></h3>
              <p>Although multi-dose phenylephrine eye drops commonly contain preservatives, preservative-free unit dose vials may be available.</p>
            </section>
      </section>









      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of PHENYLEPHRINE HYDROCHLORIDE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            eye drops,
            solution for injection,
            capsule,

            <div id="PHP77502"><a href="../medicinalForm/PHP77502.html" data-target="#PHP77502" data-action="load">Tablet</a></div>
            <div id="PHP74604"><a href="../medicinalForm/PHP74604.html" data-target="#PHP74604" data-action="load">Capsule</a></div>
            <div id="PHP74599"><a href="../medicinalForm/PHP74599.html" data-target="#PHP74599" data-action="load">Solution for injection</a></div>
            <div id="PHP77506"><a href="../medicinalForm/PHP77506.html" data-target="#PHP77506" data-action="load">Eye drops</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
